Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa.

Onoya D, Nattey C, Budgell E, van den Berg L, Maskew M, Evans D, Hirasen K, Long LC, Fox MP.

AIDS Patient Care STDS. 2017 May;31(5):205-212. doi: 10.1089/apc.2016.0291. Epub 2017 Apr 26.

2.

Changes in second-line regimen durability and continuity of care in relation to national ART guideline changes in South Africa.

Onoya D, Brennan AT, Berhanu R, van der Berg L, Buthelezi T, Fox MP.

J Int AIDS Soc. 2016 Dec 21;19(1):1-13. doi: 10.7448/IAS.19.1.20675.

3.

Growing challenges for HIV programmes in Asia: clinic population trends, 2003-2013.

De La Mata NL, Kumarasamy N, Ly PS, Ng OT, Nguyen KV, Merati TP, Lee MP, Do CD, Choi JY, Ross JL, Law MG.

AIDS Care. 2017 Oct;29(10):1243-1254. doi: 10.1080/09540121.2017.1282108. Epub 2017 Jan 29.

PMID:
28132544
4.

Predictors of treatment failure on second-line antiretroviral therapy among adults in northwest Ethiopia: a multicentre retrospective follow-up study.

Tsegaye AT, Wubshet M, Awoke T, Addis Alene K.

BMJ Open. 2016 Dec 8;6(12):e012537. doi: 10.1136/bmjopen-2016-012537.

5.

Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis.

Gomez GB, Dowdy DW, Bastos ML, Zwerling A, Sweeney S, Foster N, Trajman A, Islam MA, Kapiga S, Sinanovic E, Knight GM, White RG, Wells WA, Cobelens FG, Vassall A.

BMC Infect Dis. 2016 Dec 1;16(1):726.

6.

Newborn screening and prophylactic interventions for sickle cell disease in 47 countries in sub-Saharan Africa: a cost-effectiveness analysis.

Kuznik A, Habib AG, Munube D, Lamorde M.

BMC Health Serv Res. 2016 Jul 26;16:304. doi: 10.1186/s12913-016-1572-6.

7.

The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa.

Walensky RP, Borre ED, Bekker LG, Resch SC, Hyle EP, Wood R, Weinstein MC, Ciaranello AL, Freedberg KA, Paltiel AD.

Ann Intern Med. 2016 Sep 6;165(5):325-33. doi: 10.7326/M16-0799. Epub 2016 May 31.

9.

Cost-Effectiveness of Antivenoms for Snakebite Envenoming in 16 Countries in West Africa.

Hamza M, Idris MA, Maiyaki MB, Lamorde M, Chippaux JP, Warrell DA, Kuznik A, Habib AG.

PLoS Negl Trop Dis. 2016 Mar 30;10(3):e0004568. doi: 10.1371/journal.pntd.0004568. eCollection 2016 Mar.

10.

The High Cost of HIV-Positive Inpatient Care at an Urban Hospital in Johannesburg, South Africa.

Long LC, Fox MP, Sauls C, Evans D, Sanne I, Rosen SB.

PLoS One. 2016 Feb 17;11(2):e0148546. doi: 10.1371/journal.pone.0148546. eCollection 2016.

11.

The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.

Knight GM, Gomez GB, Dodd PJ, Dowdy D, Zwerling A, Wells WA, Cobelens F, Vassall A, White RG.

PLoS One. 2015 Dec 30;10(12):e0145796. doi: 10.1371/journal.pone.0145796. eCollection 2015.

12.

Blocking HIV-1 transmission in the female reproductive tract: from microbicide development to exploring local antiviral responses.

Eid SG, Mangan NE, Hertzog PJ, Mak J.

Clin Transl Immunology. 2015 Oct 9;4(10):e43. doi: 10.1038/cti.2015.23. eCollection 2015 Oct. Review.

13.

Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China.

Wang J, Wang Z, Liu J, Yue Y, Yang S, Huang H, He C, Liao L, Xing H, Ruan Y, Shao Y.

Sci Rep. 2015 Oct 8;5:14823. doi: 10.1038/srep14823.

14.

The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis.

Meyer-Rath G, Pienaar J, Brink B, van Zyl A, Muirhead D, Grant A, Churchyard G, Watts C, Vickerman P.

PLoS Med. 2015 Sep 1;12(9):e1001869. doi: 10.1371/journal.pmed.1001869. eCollection 2015 Sep.

15.
16.

Kericho CLinic-based ART Diagnostic Evaluation (CLADE): design, accrual, and baseline characteristics of a randomized controlled trial conducted in predominately rural, district-level, HIV clinics of Kenya.

Sawe FK, Obiero E, Yegon P, Langat RC, Aoko A, Tarus J, Kiptoo I, Langat RK, Maswai J, Bii M, Khamadi S, Shikuku KP, Close N, Sinei S, Shaffer DN.

PLoS One. 2015 Feb 23;10(2):e0116299. doi: 10.1371/journal.pone.0116299. eCollection 2015.

17.

Cost-effectiveness of antivenoms for snakebite envenoming in Nigeria.

Habib AG, Lamorde M, Dalhat MM, Habib ZG, Kuznik A.

PLoS Negl Trop Dis. 2015 Jan 8;9(1):e3381. doi: 10.1371/journal.pntd.0003381. eCollection 2015 Jan.

18.

The impact of the 2013 WHO antiretroviral therapy guidelines on the feasibility of HIV population prevention trials.

Ross E, Tanser F, Pei P, Newell ML, Losina E, Thiebaut R, Weinstein M, Freedberg K, Anglaret X, Scott C, Dabis F, Walensky R.

HIV Clin Trials. 2014 Sep-Oct;15(5):185-98. doi: 10.1310/hct1505-185.

19.

Is there scope for cost savings and efficiency gains in HIV services? A systematic review of the evidence from low- and middle-income countries.

Siapka M, Remme M, Obure CD, Maier CB, Dehne KL, Vassall A.

Bull World Health Organ. 2014 Jul 1;92(7):499-511AD. doi: 10.2471/BLT.13.127639. Epub 2014 Apr 1. Review.

20.

Combined antiretroviral and anti-tuberculosis drug resistance following incarceration.

Stott KE, de Oliviera T, Lessells RJ.

South Afr J HIV Med. 2013 Sep 1;14(3). doi: 10.7196/SAJHIVMED.957.

Supplemental Content

Support Center